Share on StockTwits

Several investment firms have updated their stock ratings and price targets on shares of CVS Caremark (NYSE: CVS) in the last week:

  • CVS Caremark was downgraded by analysts at ISI Group to an “underperform” rating. They now have a $54.00 price target on the stock, down previously from $86.00.
  • CVS Caremark had its price target raised by analysts at Barclays from $85.00 to $87.00.
  • CVS Caremark had its “overweight” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a $91.00 price target on the stock, up previously from $82.00.
  • CVS Caremark had its price target raised by analysts at Morgan Stanley from $81.00 to $85.00.
  • CVS Caremark had its price target raised by analysts at RBC Capital from $76.00 to $86.00. They now have an “outperform” rating on the stock.
  • CVS Caremark had its price target raised by analysts at Mizuho from $81.00 to $85.00. They now have a “buy” rating on the stock.
  • CVS Caremark had its price target raised by analysts at Argus from $83.00 to $85.00. They now have a “buy” rating on the stock.
  • CVS Caremark had its price target raised by analysts at Cantor Fitzgerald from $66.00 to $71.00.
  • CVS Caremark had its price target raised by analysts at Leerink Swann from $85.00 to $87.00.
  • CVS Caremark had its price target raised by analysts at Cowen and Company from $80.00 to $85.00.
  • CVS Caremark had its “neutral” rating reaffirmed by analysts at Zacks. They now have a $82.00 price target on the stock. Zacks‘ analyst wrote, “CVS posted a decent second-quarter 2014 with 16.5% year over year rise in adjusted EPS to $1.13 which also surpassed the Zacks Consensus Estimate by $0.03 as well as the company-provided guidance range of $1.08 to $1.11. Net revenue on the other hand, increased 10.7% to $34.6 billion, edging past the Zacks Consensus Estimate of $33.41 billion. The generic wave in the pharmaceutical industry continues to work in CVS’ favor, as seen in the consistent margin expansion of the company. We are also impressed with CVS’ strong guidance for 2014 where increased adjusted EPS reflects strong year-over-year growth and the company’s optimism about the future. On the contrary, the decline in front-end sales was disappointing. Moreover, the competitive landscape remains tough. We also keep an eye on the tussle for market share gain in the PBM as well as retail pharmacy segment. Thus, we reiterate our Neutral recommendation on the stock.”

Shares of CVS Caremark Co. (NYSE:CVS) traded up 0.06% during mid-day trading on Wednesday, hitting $78.72. The stock had a trading volume of 1,586,646 shares. CVS Caremark Co. has a 52 week low of $56.32 and a 52 week high of $79.43. The stock’s 50-day moving average is $77.02 and its 200-day moving average is $74.52. The company has a market cap of $91.315 billion and a P/E ratio of 19.29.

CVS Caremark Corporation (NYSE:CVS), together with its subsidiaries, is a pharmacy health care provider in the United States.

Receive News & Ratings for CVS Caremark Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Caremark Co and related companies with Analyst Ratings Network's FREE daily email newsletter.